Please login to the form below

Not currently logged in

Lannett appoints Teva’s Michael Bogda as president

He served as VP of technical operations in for Teva’s Americas division

Generic pharmaceuticals company Lannett has named Michael Bogda as its new president.

Bogda joins from Israeli firm Teva, where he served as VP for its technical operations in the Americas region.

Prior to this, Bogda held a number of roles at Barr Pharma, working his way up to the position of president and chief operating officer of Barr Laboratories. Previously, Bogda served as VP of operations for Copley Pharma.

Commenting on his new role, Bogda said: “The company has made great progress in building a vertically integrated pain management business, formed strategic alliances and developed a deep pipeline focused on controlled substances.

“I am enthusiastic and energised about the opportunities ahead and look forward to working to continue to execute Lannett's strategic priorities.”

Former president Arthur Bedrosian will remain in at the company in his current CEO role.

Bedrosian said: “To address our rapid growth, as well as our long-term succession planning efforts, we embarked upon a search for a high quality individual and we found one.

“Michael brings a global perspective, in addition to extensive operations, merger and acquisitions and business integration experience. We welcome Michael and look forward to his insight as we look to take our company to its next stage of growth and development.”

22nd December 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge